LRIG1和EGFR在膀胱移行细胞癌中的表达及临床意义

目的：探讨LRIG1和表皮生长因子受体（EGFR）在膀胱移行细胞癌中的表达及临床意义。方法：采用免疫组织化学SP法检测LRIG1和EGFR蛋白在52例膀胱移行细胞癌和8例正常膀胱组织中的表达情况，并结合临床资料进行分析。结果：52例膀胱癌组织中，LRIG1和EGFR蛋白的阳性表达率分别为38．5％（20／52）和65．4％（34／52）。8例正常膀胱组织中，LRIG1均呈阳性表达，EGFR均呈阴性表达。随着膀胱癌病理分级和临床分期的增高，LRIG1表达显著减少，而EGFR表达增高。LRIG1蛋白阳性表达率在未复发组高于复发组，EGFR蛋白阳性表达率在未复发组低于复发组，差异有统计学意义（P〈0．05）。LRIG1与EGFR的表达强度之间呈明显负相关（r=-0．505，P=0．000）。结论：LRIG1和EGFR可以作为判定膀胱移行细胞癌恶性程度及复发的参考指标。

The expressions and clinical significance of LRIG1 and EGFR in bladder transitional cell carcinoma

Objective:To investigate the expressions of LRIG1 and epithelial growth factor receptor (EGFR) in bladder transitional cell carcinoma and their clinical significance.Methods:Expressions of LRIG1 and EGFR in 52 specimens of bladder transitional cell carcinoma and 8 specimens of normal bladder tissues were detected by SP of immunohistochemistry. The results were analyzed in relation to the clinical data.Results:The positive rates of LRIG1 and EGFR in bladder carcinoma were 38.5%(20/52) and 65.4%(34/52), respectively. All 8 normal bladder tissues had positive expression of LRIG1 and negative expression of EGFR. The abnormal expressions of LRIG1 and EGFR were related to the tumor grade ,clinical stage and recurrence (P<0.05). The expression of LRIG1 negatively correlated with that of EGFR (r=-0.505,P=0.000).Conclusions:The expressions of LRIG1 and EGFR may be used as parameters for assessing the malignancy and recurrence of bladder transitional cell carcinoma.